Canopus BioPharma Current Liabilities vs. Cash Flow From Operations
| CBIA Stock | USD 0.0001 0.00 0.00% |
For Canopus BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Canopus BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Canopus BioPharma Incorporated utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Canopus BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Canopus BioPharma Incorporated over time as well as its relative position and ranking within its peers.
Canopus |
Canopus BioPharma Cash Flow From Operations vs. Current Liabilities Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Canopus BioPharma's current stock value. Our valuation model uses many indicators to compare Canopus BioPharma value to that of its competitors to determine the firm's financial worth. Canopus BioPharma Incorporated is number one stock in current liabilities category among its peers. It also is number one stock in cash flow from operations category among its peers making about 0.84 of Cash Flow From Operations per Current Liabilities. The ratio of Current Liabilities to Cash Flow From Operations for Canopus BioPharma Incorporated is roughly 1.19 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Canopus BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Canopus BioPharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Canopus Cash Flow From Operations vs. Current Liabilities
Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Canopus BioPharma |
| = | 2.36 M |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Canopus BioPharma |
| = | 1.98 M |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Canopus Cash Flow From Operations Comparison
Canopus BioPharma is currently under evaluation in cash flow from operations category among its peers.
Canopus BioPharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Canopus BioPharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Canopus BioPharma will eventually generate negative long term returns. The profitability progress is the general direction of Canopus BioPharma's change in net profit over the period of time. It can combine multiple indicators of Canopus BioPharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. Canopus BioPharma Incorporated is based in Santa Monica, California. Canopus Biopharma is traded on OTC Exchange in the United States.
Canopus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Canopus BioPharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Canopus BioPharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Canopus BioPharma's important profitability drivers and their relationship over time.
Use Canopus BioPharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Canopus BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Canopus BioPharma will appreciate offsetting losses from the drop in the long position's value.Canopus BioPharma Pair Trading
Canopus BioPharma Incorporated Pair Trading Analysis
The ability to find closely correlated positions to Canopus BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Canopus BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Canopus BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Canopus BioPharma Incorporated to buy it.
The correlation of Canopus BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Canopus BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Canopus BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Canopus BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Canopus BioPharma position
In addition to having Canopus BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities - Regulated Electric Thematic Idea Now
Utilities - Regulated Electric
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Utilities - Regulated Electric theme has 6 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities - Regulated Electric Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Canopus Pink Sheet
To fully project Canopus BioPharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Canopus BioPharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Canopus BioPharma's income statement, its balance sheet, and the statement of cash flows.